Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation

Main Article Content

Panagiotis J. Vlachostergios

Keywords

angiogenesis, molecular biomarker, mutation, immunotherapy, renal cell carcinoma

Abstract

Clear cell renal cell carcinoma (ccRCC) represents the most common subtype of renal cell carcinoma (RCC). In spite of recent advances in the treatment armamentarium and outcomes with the combined use of immune checkpoint and angiogenesis inhibitors, prediction of responses and selection of patients remain a challenge. This is a case of ccRCC with recurrence to the liver 1 year following right radical nephrectomy, who rapidly progressed on frontline therapy with axitinib/pembrolizumab. The clinical course and targeted tumor sequencing findings are discussed. In addition to established clinical prognostication in RCC, several surrogate markers of efficacy or/and resistance have been proposed for immu-notherapy or/and anti-angiogenic therapy. Since the majority of patients will still progress after these combinations, it is becoming increasingly important to develop robust predictive biomarkers to guide patient selection and sequencing of targeted therapies.

Abstract 321 | PDF Downloads 46 HTML Downloads 12 XML Downloads 11

References

1. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 Mar 21;380(12):1116–27. http://dx.doi.org/10.1056/NEJMoa1816714
2. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 Mar 21;380(12):1103–15. http://dx.doi.org/10.1056/NEJMoa1816047
3. Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, et al. Updated efficacy results from the JAVELIN renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020 Apr 24. pii: S0923-7534(20)39308-X. http://dx.doi.org/10.1016/j.annonc.2020.04.010
4. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study. Lancet Oncol. 2013 Feb;14(2):141–8. http://dx.doi.org/10.1016/S1470-2045(12)70559-4
5. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277–90. http://dx.doi.org/10.1056/NEJMoa1712126
6. NIH, National Cancer Institute, Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Kidney and Renal Pelvis Cancer [Internet]. [Accessed 2020 May 1]. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html
7. Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019 Dec 20;7(1):354. http://dx.doi.org/10.1186/s40425-019-0813-8
8. Park K, Tran H, Eng KW, Ramazanoglu S, Marrero Rolon RM, Scognamiglio T, et al. Performance characteristics of a targeted sequencing platform for simultaneous detection of single nucleotide variants, insertions/deletions, copy number alterations, and gene fusions in cancer genome. Arch Pathol Lab Med. 2020 Feb 11. http://dx.doi.org/10.5858/arpa.2019-0162-OA
9. Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to systemic therapies in clear cell renal cell carcinoma: Mechanisms and management strategies. Mol Cancer Ther. 2018 Jul;17(7):1355–64. http://dx.doi.org/10.1158/1535-7163.MCT-17-1299
10. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018 Apr 3;23(1):313–26.e5. http://dx.doi.org/10.1016/j.celrep.2018.03.075
11. Hsieh JJ, Le VH, Oyama T, Ricketts CJ, Ho TH, Cheng EH. Chromosome 3p loss-orchestrated VHL, HIF, and epigenetic deregulation in clear cell renal cell carcinoma. J Clin Oncol. 2018 Oct 29:JCO2018792549. http://dx.doi.org/10.1200/JCO.2018.79.2549
12. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008 Sep;180(3):860–5; discussion 865–6.
13. Messai Y, Gad S, Noman MZ, Le Teuff G, Couve S, Janji B, et al. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel-Lindau gene mutation status. Eur Urol. 2016 Oct;70(4):623–32. http://dx.doi.org/10.1016/j.eururo.2015.11.029.
14. Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A. 2014;111:13373–8. https://doi.org/10.1073/pnas.1404848111
15. Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, et al. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther. 2015;14:101–10. https://doi.org/10.1158/1535-7163.MCT-14-0094
16. Gu YF, Cohn S, Christie A, McKenzie T, Wolff N, Do QN, et al. Modeling renal cell carcinoma in mice: Bap1 and Pbrm1 inactivation drive tumor grade. Cancer Discov. 2017 Aug;7(8):900–17. http://dx.doi.org/10.1158/2159-8290.CD-17-0292
17. Figueiredo CR, Kalirai H, Sacco JJ, Azevedo RA, Duckworth A, Slupsky JR, et al. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development. J Pathol. 2020 Apr;250(4):420–39. http://dx.doi.org/10.1002/path.5384
18. Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 2019 Feb 18;11(1):8. http://dx.doi.org/10.1186/s13073-019-0620-3
19. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 Aug 22;369(8):722–31. http://dx.doi.org/10.1056/NEJMoa1303989
20. Voss MH, Kuo F, Chen D, Marker M, Patel P, Redzematovic A, et al. Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy. J Clin Oncol. 2017 May 20;35(15_Suppl):4523–3. http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.4523
21. Xiong D, Wang Y, Singavi AK, Mackinnon AC, George B, You M. Immunogenomic landscape contributes to hyperpro-gressive disease after anti-PD-1 immunotherapy for cancer. iScience. 2018 Nov 30;9:258–77. http://dx.doi.org/10.1016/j.isci.2018.10.021
22. Nouhaud FX, Blanchard F, Sesboue R, Flaman JM, Sabourin JC, Pfister C. Clinical relevance of gene copy number variation in metastatic clear cell renal cell carcinoma. Clin Genitourin Cancer. 2018 Aug;16(4):e795–805. http://dx.doi.org/10.1016/j.clgc.2018.02.013
23. Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank KG, Paschen A. Tumor CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance. J Natl Cancer Inst. 2018 Jun 1;110(6):677–81. http://dx.doi.org/10.1093/jnci/djx271
24. Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, et al. Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma. Clin Cancer Res. 2019 Nov 1;25(21):6511–23. http://dx.doi.org/10.1158/1078-0432.CCR-19-0475
25. Small J, Washburn E, Millington K, Zhu J, Holder SL. The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors. Oncotarget. 2017 Jul 27;8(56):95116–34. http://dx.doi.org/10.18632/oncotarget.19618
26. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–57. http://dx.doi.org/10.1038/s41591-018-0235-z
27. Choueiri TK, Albiges L, Haanen JBAG, Larkin JMG, Uemura M, Pal SK, et al. Biomarker analyses from JAVELIN renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J Clin Oncol. 2019;May 20;37(15_Suppl):101–1. http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.101
28. Rini B, Huseni M, Atkins MB, McDermott DF, Powles TB, Escudier B, et al. Molecular correlates differentiate response to atezolizumab + bevacizumab vs sunitinib. Ann Oncol. 2018 October 20;29(Suppl_8):LBA31. https://doi.org/10.1093/annonc/mdy424.037